High dose chemotherapy with stem cell rescue for breast cancer: current status and future directions.

作者: Anthony D. Elias

DOI: 10.3233/BD-2001-14107

关键词: Randomized controlled trialHigh dose chemotherapySurgeryModalitiesMammary glandBreast cancerInternal medicineChemotherapyMetastatic breast cancerMedicineOncologyImmunotherapy

摘要: Dose intensification of particular chemotherapy agents can produce high, complete and overall response rates in women with locally advanced or metastatic breast cancer. High dose stem cell rescue is currently a controversial strategy, not only as component the standard care, but even an investigative field. This review covers preclinical clinical underpinnings high therapy for cancer, including selected phase II trials III reported to date both Proof principle utility this approach requires further maturation data completion ongoing randomized trials. Nonetheless, results are sufficiently compelling support research grants, particularly effort develop multicycle approaches integrate new modalities, such immunotherapy, into framework therapy.

参考文章(73)
Beverly A. Teicher, Emil Frei, Modulation of antitumor alkylating agents (AA). Cancer treatment and research. ,vol. 57, pp. 261- 295 ,(1991) , 10.1007/978-1-4615-3872-1_13
J. J. Vredenburgh, G. Broadwater, K. DeSombre, C. Tyer, Donald Berry, Robert C Bast, W. P. Peters, O. Silva, W. P. Petros, The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support Biology of Blood and Marrow Transplantation. ,vol. 3, pp. 91- 97 ,(1997)
K Antman, L Ayash, A Elias, C Wheeler, M Hunt, J P Eder, B A Teicher, J Critchlow, J Bibbo, L E Schnipper, A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. Journal of Clinical Oncology. ,vol. 10, pp. 102- 110 ,(1992) , 10.1200/JCO.1992.10.1.102
M Crump, P E Goss, M Prince, C Girouard, Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. Journal of Clinical Oncology. ,vol. 14, pp. 66- 69 ,(1996) , 10.1200/JCO.1996.14.1.66
A M Gianni, S Siena, M Bregni, M Di Nicola, S Orefice, F Cusumano, B Salvadori, A Luini, M Greco, R Zucali, F Rilke, M Zambetti, P Valagussa, G Bonadonna, Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. Journal of Clinical Oncology. ,vol. 15, pp. 2312- 2321 ,(1997) , 10.1200/JCO.1997.15.6.2312
Craig R Nichols, Guido Tricot, Stephen D Williams, Koen van Besien, Patrick J Loehrer, Bruce J Roth, Luke Akard, Ron Hoffman, Robert Goulet, Steven N Wolff, None, Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. Journal of Clinical Oncology. ,vol. 7, pp. 932- 939 ,(1989) , 10.1200/JCO.1989.7.7.932
W Hryniuk, M N Levine, Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. Journal of Clinical Oncology. ,vol. 4, pp. 1162- 1170 ,(1986) , 10.1200/JCO.1986.4.8.1162
W R Bezwoda, L Seymour, R D Dansey, High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. Journal of Clinical Oncology. ,vol. 13, pp. 2483- 2489 ,(1995) , 10.1200/JCO.1995.13.10.2483
L J Ayash, C Wheeler, D Fairclough, G Schwartz, E Reich, D Warren, L Schnipper, K Antman, E Frei, A Elias, Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. Journal of Clinical Oncology. ,vol. 13, pp. 2043- 2049 ,(1995) , 10.1200/JCO.1995.13.8.2043